Nephrotoxicity associated with anticancer agents: perspective on onconephrology from nephrologists.

Abstract

Nephrotoxicity is one of the most important complications in cancer patients. In particular, acute kidney injury (AKI) is known to be associated with discontinuing effective oncological treatments, longer hospitalizations, increased costs, and a higher risk of death. In addition to acute kidney injury, clinical signs associated with nephrotoxicity during treatment with anticancer agents include chronic kidney disease, proteinuria, hypertension, electrolyte abnormalities, and other characteristic manifestations. Many of these signs are caused both by cancer treatment as well as by cancer itself. Therefore, it is important to carefully recognize whether the underlying causes of renal impairment in cancer patients are cancer-related, treatment-related, or both. This review describes the epidemiology and pathophysiology of anticancer agent-induced acute kidney injury, proteinuria, hypertension, and other characteristic manifestations.

• Authors: Takeshi Matsubara, Hideki Yokoi, Hiroyuki Yamada, Motoko Yanagita
• Journal: International journal of clinical oncology (Int J Clin Oncol) Vol. 28 Issue 5 Pg. 625-636 (May 2023) ISSN: 1437-7772 [Electronic] Japan
• PMID: 36872414 (Publication Type: Journal Article, Review)
• Copyright: © 2023. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.

Chemical References

• Antineoplastic Agents

Topics

• Humans
• Nephrologists
• Antineoplastic Agents (adverse effects)
• Acute Kidney Injury (chemically induced, epidemiology)
• Proteinuria (chemically induced)
• Hypertension
• Neoplasms (drug therapy, complications)